Impact of Vutrisiran on Exploratory Cardiac Parameters in Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

202449 citationsJournal Articlehybrid Open Access

Authors

Pablo García‐Pavía · Universidad Francisco de Vitoria

Martha Grogan · Mayo Clinic

Parag Kale · Baylor University Medical Center

John L. Berk · Boston University

Mathew S. Maurer · Columbia University Irving Medical Center

Isabel Conceição · Centro Hospitalar Lisboa Norte

Marcelo F. Di Carli

Abstract

Vutrisiran demonstrated evidence of potential benefit on cardiac manifestations in patients with ATTRv amyloidosis with polyneuropathy, with an acceptable safety profile.

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Protein Kinase Regulation and GTPase Signaling Cellular transport and secretion

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Heart Failure

Volume 26, Issue 2, pp. 397-410

DOI: 10.1002/ejhf.3138

Field-Weighted Citation Impact: 11.51